better accuracy in detecting cnv and sv mutations
The assessment of somatic variants is crucial for cancer diagnostics, companion diagnostics, and target selection in drug development.
The Genoox platform scales and enhances the ability to produce actionable insights from the latest scientific literature, clinical trials, and conference proceedings.
the genoox advantage
for timely diagnosis and treatment
following AMP, NCCN & ASCO guidelines
SNV’s, CNV’s, and SV genomic alteration
supporting all relevant sequencing platforms (WGS, WES, and panels, both disease state & custom)
Multiple analysis mode
tumor only, paired normal-tumor or tumor-blood/tissue analysis
enabling quality results with low DNA sample volumes as often seen with FFPE - without loss in accuracy
Customizable reporting tools
to be shared with physicians and patients